Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 11/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NMT1 | P30419 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | NMT2 | O60551 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29409630 | 1.00 | TP53 (0.62) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL29409637 | 1.00 | TP53 (0.62) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL18987698 | 0.91 | TP53 (0.54) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL620724 | 0.88 | MAPT (0.61) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL6197990 | 0.87 | TP53 (0.63) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL544894 | 0.87 | MAPT (0.62) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL649687 | 0.85 | PDE5A (0.60) | MAPTMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL29896388 | 0.85 | MAPT (0.54) | TP53MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL620513 | 0.85 | MAPT (0.53) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL618676 | 0.85 | MAPT (0.53) | TP53MAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486234-B2 | PAPD5 inhibitors and methods of use thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| CN-119798159-A | PAPD5 inhibitors and methods of use thereof | 儿童医学中心公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20220274928-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION | 2022-09-01 | — | — | US | disclosed |
| EP-3959197-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-113993848-A | Inhibitors of PAPD5 and methods of use thereof | 儿童医学中心公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020219729-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219729-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-10-29 | — | — | WO | disclosed |
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1427421-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | Amgen Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003018021-A1 | 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS | AMGEN INC. (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274928-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, PARP15, TERT | TP53 75/4885MAPT 1712/4885MEN1 3400/4885 |
| US-12486234-B2 | PAPD5 inhibitors and methods of use thereof | POT1, PARP15, TERT | TP53 75/4885MAPT 1712/4885MEN1 3400/4885 |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | TP53 34/4885MAPT 4491/4885MEN1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.